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  ABSTRACT 
  Objective      To determine the effect of chondroitin sulphate 
(CS) treatment on cartilage volume loss, subchondral bone 
marrow lesions (BML), synovitis and disease symptoms in 
patients with knee osteoarthritis (OA).   
  Methods      In this pilot multicentre, randomised, double-
blind, controlled trial in primary knee OA, 69 patients with 
clinical signs of synovitis were randomised to receive CS 
800 mg or placebo once daily for 6 months followed by 
an open-label phase of 6 months in which patients in both 
groups received CS 800 mg once daily. Cartilage volume 
and BML were assessed by MRI at baseline and at 6 and 
12 months; synovial membrane thickness was assessed 
at baseline and at 6 months.   
  Results      The CS group showed signiﬁ  cantly less cartilage 
volume loss than the placebo group as early as 6 months 
for the global knee (p=0.030), lateral compartment 
(p=0.015) and tibial plateaus (p=0.002), with 
signiﬁ  cance persisting at 12 months. Signiﬁ  cantly lower 
BML scores were found for the CS group at 12 months 
in the lateral compartment (p=0.035) and the lateral 
femoral condyle (p=0.044). Disease symptoms were 
similar between the two groups.   
  Conclusion      CS treatment signiﬁ  cantly reduced the 
cartilage volume loss in knee OA starting at 6 months of 
treatment, and BML at 12 months. These ﬁ  ndings suggest 
a joint structure protective effect of CS and provide new in 
vivo information on its mode of action in knee OA.           
  INTRODUCTION 
  Of all musculoskeletal conditions, osteoarthritis 
(OA) has the highest prevalence, affecting a sig-
niﬁ   cant percentage of the ageing population.    1     –      3    
Management of OA requires a long-standing combi-
nation of pharmacological and non- pharmacological 
treatment modalities to relieve pain and to main-
tain joint mobility in daily life.    4    Many attempts 
have therefore been made during the past decades 
to ﬁ  nd treatments that can not only offer pain man-
agement, but also alter the course of the disease 
with the lowest possible risk of adverse events. 
Only a few medications have been recognised by 
clinical trials to potentially inﬂ  uence the course of 
OA beneﬁ  cially: these include chondroitin sulphate 
(CS),    5     –      8    glucosamine,    9     –      11    diacerein,    12    doxycycline    13    
and licofelone.    14    However, all previous disease-
modifying OA drug (DMOAD) studies by other 
groups have used conventional x-rays, which, 
although recognised by the authorities, might not 
have fully explored the drugs’ protective effect as 
this technique allows for only an indirect assess-
ment of the cartilage. Recent advances in MRI have 
enabled investigators to quantitatively and reliably 
assess cartilage thickness and volume, as well as 
the other joint structural changes occurring in the 
subchondral bone, menisci and synovium.    15     –      22    The 
usefulness of MRI technology in the context of clin-
ical trials exploring DMOAD effects has recently 
been demonstrated.    14        23    
  CS belongs to the glycosaminoglycans and is a 
major component of articular cartilage. On OA joint 
tissues, CS has been shown to modify the chondro-
cyte death process, to improve the anabolic/cata-
bolic balance of the extracellular cartilage matrix, 
to reduce some pro-inﬂ   ammatory and catabolic 
factors, and to reduce the resorptive properties 
of subchondral bone osteoblasts.    24     –      35    Moreover, 
meta-analyses of randomised placebo-controlled 
trials in knee OA patients have demonstrated the 
efﬁ  cacy of CS to relieve OA joint pain.    36     –      38    CS at a 
dose of 800 mg orally once daily has been shown 
to slow signiﬁ  cantly the rate of joint space narrow-
ing (JSN) over a period of 2 years in patients with 
symptomatic radiographic knee OA.    7        8        39        40    The 
aim of this study was to conﬁ  rm the ﬁ  ndings from 
x-ray-based trials on the effect of CS on cartilage 
volume loss in knee OA patients, yet at a much 
earlier time period by using MRI, and to evalu-
ate the effect of treatment on subchondral bone 
lesions and synovitis severity.   
  PATIENTS  AND  METHODS 
  Study  design 
  The present pilot study is a National Institutes 
of Health (NIH)-registered (NCT00604539) mul-
ticentre, randomised, double-blind, controlled 
trial comparing CS with placebo in patients with 
primary knee OA. The double-blind phase was 
of 6 months duration, followed by an open-label 
phase of 6 months of CS treatment for both groups. 
The study was conducted from February 2008 to 
October 2009.   
  Patient  selection 
  Seventy patients of both sexes between 40 and 
80 years of age were recruited from outpatient 
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  Treatment  compliance 
  The number of tablets of the study drug taken was calculated 
from the drug dispensation log. The compliance index was cal-
culated as the percentage of the rated drug doses taken between 
the date of dispensation and the date of return of the study 
drugs. To remain in the study, a global compliance index of 
≥75% was mandatory.   
  Study  schedule 
  Patients had a screening visit 7–14 days prior to baseline MRI 
including physical examination for joint swelling or effusion, 
x-ray and blood samples for routine laboratory tests to assess 
eligibility. A follow-up physical examination was performed at 
3, 6 and 12 months. Patients were contacted every 45 days to 
report possible adverse events.   
  Outcome  measures 
  Knee  MRI  acquisitions 
  MRI was performed at baseline and at 6 and 12 months on 1.5 
T scanners (Siemens, Erlangen, Germany; and General Electric, 
Milwaukee, Wisconsin, USA) using a standard knee coil. The 
sequence acquisitions were as previously described    14        15        43    (see 
online supplementary text). 
  Cartilage  volume 
  Cartilage volume was measured by two trained readers 
(J Thériault and A Pelletier)   using the computer program 
Cartiscope (ArthroVision, Montreal, Canada) as previously 
described.    43        44    The readers were blinded to treatment and 
to MRI examination time points except for baseline. The 
change in knee cartilage volume was obtained by subtracting 
the follow-up volume from the initial (baseline) volume. The 
change in cartilage volume over time was calculated for the 
entire knee (global, comprising condyles plus tibial plateaus) 
and subregions including the condyles, tibial plateaus, the 
medial and lateral compartments (condyle plus tibial plateau), 
the medial and lateral condyle and tibial plateau, and the tro-
chlea.    16        45    The trochlea corresponds to the area of the femoral 
cartilage in contact with the patella.    16    The patellar cartilage 
volume was not assessed. The reproducibility of the method 
has previously been demonstrated to be excellent.    43      
  Synovial  membrane  thickness 
  Synovial membrane imaging was acquired as previously 
described    21    (see online supplementary text). The extent of syn-
ovitis was assessed by measuring its thickness in mm in four 
regions of interest: the medial and lateral articular recess and the 
medial and lateral border of the suprapatellar bursa.    21      
  Bone  marrow  lesions 
  Assessment of bone marrow lesions (BML) was performed in 
the same MRI sequences used for the cartilage assessment as 
previously described.    46    The extent of the BML was assessed for 
the global knee and the subregions using the following scale: 
0 = absence, 1 = <25%, 2 = 25–50%, and 3 = >50% of the surface 
of the respective region regardless of the presence of additional 
smaller lesions. Reliability of the scoring system for subchondral 
bone changes was found to be excellent.    46        
  Symptoms 
  Pain, function and stiffness were assessed at baseline and at 1.5, 
3, 6 and 12 months using the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) questionnaire and 
the VAS for pain. The impact on quality of life was also assessed 
rheumatology clinics in the province of Québec, Canada. 
Inclusion criteria were primary OA of the knee diagnosed 
according to the clinical and radiological criteria of the American 
College of Rheumatology (ACR)    41    with clinical signs of syno-
vitis (warmth, swelling or effusion), a disease severity grade 
2–3 based on the Kellgren–Lawrence radiographic system,    42    a 
minimal medial joint space width (JSW) of 2 mm on standing 
knee x-ray, and a visual analogue scale (VAS) pain index of 
at least 40 mm while walking. Concomitant femoropatellar 
OA was not quantiﬁ  ed on x-ray. Participants were required 
to have no signiﬁ  cant laboratory abnormalities. If both knees 
were affected by OA, the knee with the more pronounced 
symptoms was selected if within inclusion criteria. 
  Exclusion criteria were the presence of another rheumatic 
condition leading to secondary OA (such as rheumatoid 
arthritis or calcium pyrophosphate dehydrate deposition dis-
ease), allergy to CS, contraindications to MRI, progressive 
serious medical conditions (such as cancer, AIDS or end-stage 
renal disease), impossibility of participating for the total dura-
tion of the study and attending the visits, as well as inabil-
ity to give informed consent. Patients were also excluded if 
they were currently, or were within the 3 months prior to 
inclusion, being treated with corticosteroids, indomethacin, 
glucosamine, CS or radioactive synovectomy, or within the 
6 months preceding inclusion, intra-articular treatment with 
hyaluronic acid. 
  Patients were randomly assigned to receive either CS 
800 mg (two capsules of 400 mg each; Condrosan, CS Bio-
Active; Bioibérica S.A., Barcelona, Spain) or placebo once 
daily for the ﬁ  rst 6 months (double-blind phase) followed by 
6 months of treatment with 800 mg CS once daily for both 
groups (open-label phase). Subjects started study medication 
at baseline visit according to the randomisation. Condrosan is 
a prescription drug containing highly puriﬁ  ed chondroitins 4- 
and 6-sulphate of bovine origin in a concentration of not less 
than 98%. It has an average molecular weight of ~15–16 kDa, 
and an intrinsic viscosity of ~0.02–0.06 m  3  /kg.   This product 
has been approved as a prescription treatment for OA in many 
European countries.   
    Prior and concomitant treatment 
  Treatment with medication for osteoporosis at baseline was 
continued, as were non-steroidal anti-inﬂ  ammatory  drugs 
(NSAIDs), in an unmodiﬁ  ed manner for the entire duration of 
the study if so wished. The medications and other treatments 
in use for intercurrent illnesses were recorded at the baseline 
visit and during the study whenever these treatments were 
modiﬁ  ed.   
  Rescue  medication 
  Paracetamol up to 3 g/day was allowed as a rescue pain medica-
tion. During the open-label phase (from month 6 to 12) NSAIDs 
were also allowed when needed. The treatment had to be inter-
rupted 24 h before all follow-up visits.   
  Blinding 
  The investigators, subjects and sponsors were blinded to the 
allocated treatment for the ﬁ  rst 6 months. Through central ran-
domisation, sealed coded tamper-proof envelopes, specifying 
the treatment group for each study drug kit number, were pro-
vided to each centre. The envelopes were to be opened only in 
the event of an emergency.   
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pleted the study (  ﬁ  gure 1  ). Fifty-four (78%) patients completed 
both phases.   
  Baseline  characteristics 
  The baseline characteristics (  table 1  ) were similarly distributed 
between the two treatment groups with the exception that 
patients in the CS group had a younger mean age.     
  Cartilage  volume 
  The data (  table 2   and   ﬁ  gure 2  ) revealed that patients in the CS 
group compared with those in the placebo group experienced a 
signiﬁ  cant reduction in cartilage volume loss in the global knee 
at 6 months (p=0.030) that persisted at 12 months (p=0.021). A 
similar signiﬁ  cant reduction was seen at both 6 and 12 months 
in the lateral compartment (p=0.015 and p=0.004, respectively) 
and the tibial plateaus (p=0.002 and p=0.017, respectively). 
Moreover, the reduction in both the lateral and medial tibial 
plateau was statistically different at 6 months (p=0.018 and 
p=0.016, respectively), with a trend at 12 months (p=0.068 and 
p=0.052, respectively). The lateral condyle also demonstrated a 
trend towards a reduction at 6 months (p=0.062) and a signiﬁ  -
cant difference at 12 months (p=0.006). No difference was seen 
in the trochlea (  table 2  ). After correction for age and concomi-
tant osteoporosis treatment the results remained unchanged 
with the exception of the global knee with age (p=0.052) and 
the lateral and medial tibial plateau, which became statistically 
signiﬁ  cant when adjusted for the treatment with bisphospho-
nates (  table 2  ).       
  BML  score 
  The BML data (  table 3  ) showed no differences between the two 
groups at 6 months. However, at 12 months a trend favouring the 
CS group was found for the global knee (p=0.062), with a signiﬁ  -
cant difference for the lateral compartment (p=0.035) and the lat-
eral condyle (p=0.044). No difference was found in the trochlea.     
at baseline and at 3, 6 and 12 months using the Short Form 36 
General Health (SF-36) questionnaire.   
  Statistical  analysis 
  Descriptive statistics were performed for all variables in the 
study. Measures of central tendency (mean, median) and disper-
sion (SD) were performed for all continuous variables and a pro-
portion calculated for categorical variables. 
  p Values were assessed by analysis of covariance (ANCOVA) 
for which the dependent variable was the cartilage volume at 6 
and 12 months, and the independent variables were the cartilage 
volume at baseline and the treatment. Adjustment was made for 
age and concomitant treatment with bisphosphonates, which 
could have had an inﬂ  uence on the subchondral bone. BML 
scores were assessed by the non-parametrical two-sided Mann–
Whitney U test. For cartilage and BML, differences between 
the two groups were assessed for the global knee as well as the 
subregions. Comparison of synovial membrane thickness and 
pain levels between the two groups was assessed by analysis of 
variance (ANOVA) and joint swelling by Fisher’s exact test. The 
analyses on the according-to-protocol   population were done 
separately for the double-blind phase (0–6 months) and for the 
additional open-label phase (0–12 months). A p value less than 
5% was considered statistically signiﬁ  cant.     
  Endpoints 
  This study focused on the main structural changes observed in 
the synovial membrane (primary endpoint), cartilage and bone, 
as well as the pain levels (co-endpoints).     
  RESULTS 
  Seventy patients were enrolled in the study; 69 were included 
as one patient was found not to meet the eligibility criteria after 
enrolment. Sixty-two (88.6%) patients completed the double-
blind phase of the study. Fifty-eight patients continued the study 
and entered the open-label phase, 54 (93.1%) of whom com-
  Figure  1         Patient disposition. CS, chondroitin sulphate; DB, double-blind; OL, open-label.       
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function) or quality of life (SF-36) at any time point of the study 
was observed (change in VAS for CS and placebo, respectively, 
from baseline to 6 months: −14.8±23.7 mm, −20.3±22.1 mm, 
p=0.359; from baseline to 12 months: −21.0±27.1 mm, 
−24.7±25.0 mm, p=0.607. Change in WOMAC pain sub-
scale, respectively, from baseline to 6 months: −79.7±105.6, 
−94.4±96.9, p=0.572; from baseline to 12 months: −99.2±96.7, 
−124.4±85.3, p=0.327; further data not shown). Paracetamol 
(rescue medication) was used by 79% of the patients (double-
blind n=69, CS n=27, placebo n=28, p=0.766). In the open-label 
phase (month 6 to 12) NSAID rescue was allowed and used by 
76% (open-label n=58, CS n=25, placebo n=19, p=0.761).   
  Safety 
  Non-serious adverse events were equally distributed within the 
two treatment groups except for infections and skin disorders, 
which were more frequent in the CS group   (    table 4    )  . None of 
them were ascribed beyond any doubt to the treatment, nor were 
the serious adverse events (SAE) related to the medication.       
  DISCUSSION 
  The present pilot study provides, for the ﬁ  rst time, evidence of 
the structure protective effect of CS in knee OA patients as early 
as 6 months into treatment. In addition, the pronounced reduc-
tion in cartilage loss found in the lateral tibiofemoral compart-
ment was also associated with a reduction in the size of BML. 
This ﬁ  nding is interesting as BML are believed to be associated 
with the progression of cartilage lesions.    46     –      51    
  This study is the ﬁ  rst to use quantitative MRI to assess the 
DMOAD potential of CS in knee OA patients, bringing impor-
tant information to a ﬁ  eld in which the results have been con-
tradictory in the past. The positive results are in line with a 
number of studies using x-ray technology    5     –      8    and with a recent 
meta-analysis that reported CS to be effective in reducing JSN.    52    
However, another recent meta-analysis including x-ray trials of 
  Synovitis 
  No difference was found between the two groups during the 
double-blind phase for the changes in the mean global syn-
ovial thickness (both were −0.1 mm) and in the percentage 
of subjects having joint swelling (CS, 20%; placebo, 23.5%; 
p=0.767). Interestingly, patients on concomitant CS and NSAID 
treatment (n=8) (1.3±0.3 mm) at 6 months demonstrated sig-
niﬁ   cantly (p=0.029) less synovial membrane thickness than 
the placebo group receiving NSAIDs (n=10) (1.6±0.3 mm) and 
a lower incidence of joint swelling (CS, 0%; placebo, 11.4%; 
p=0.092).  
  Symptoms  and  function 
  No signiﬁ  cant difference in disease symptoms assessed by VAS 
and WOMAC questionnaires (WOMAC total, pain, stiffness and 
  Table  2         Cartilage volume loss (%) versus baseline   
 Region   Month 
 CS   Placebo   p  Values 
 Mean   SD   Mean   SD   –   Age*   BP† 
Global 6 −2.87 3.26 −4.67 3.39 0.030 0.052 0.011
12 −3.71 3.14 −6.12 4.59 0.021 0.036 0.014
Lateral compartment 6 −1.5 3.4 −3.69 4.47 0.015 0.028 0.013
12 −1.51 3.67 −5.04 5.02 0.004 0.006 0.002
Medial compartment 6 −4.43 5.27 −5.9 4.7 0.237 0.308 0.116
12 −6.17 4.67 −7.73 7.33 0.202 0.276 0.201
Condyles 6 −4.91 4.56 −5.55 4.86 0.309 0.493 0.187
12 −5.52 4.37 −7.32 5.2 0.077 0.133 0.061
Lateral condyle 6 −2.54 4.73 −4.38 4.94 0.062 0.123 0.072
12 −1.67 4.66 −5.55 6.24 0.006 0.010 0.005
Medial condyle 6 −7.49 7.71 −6.84 7.07 0.971 0.847 0.673
12 −9.59 7.7 −9.34 7.84 0.731 0.906 0.719
Tibial plateaus 6 0.02 3.59 −2.96 4.12 0.002 0.002 0.001
12 −1.09 3.02 −4.22 5.12 0.017 0.022 0.011
Lateral tibial plateau 6 −0.05 3.59 −2.36 6.2 0.018 0.017 0.007
12 −1.2 4.49 −4.54 6.19 0.068 0.090 0.040
Medial tibial plateau 6 0.55 6.06 −3.92 6.22 0.016 0.016 0.009
12 −0.44 5.12 −4.84 8.71 0.052 0.059 0.047
Trochlea 6 −1.13 4.35 −1.78 5.87 0.486 0.687 0.389
12 −1.71 6.22 −4.03 6.24 0.129 0.175 0.068
      Data are shown for the percentage change in cartilage volume. 
  p Values of the corresponding subregions were assessed by analysis of covariance (ANCOVA) where the dependent variable was 
the cartilage volume at 6 and 12 months, and the independent variables were the cartilage volume at baseline and the treatment. 
Additional adjustment was made for *age and concomitant treatment with †bisphosphonates. 
  n=32/30 for CS, n=28/22 for placebo at 6 and 12 months, respectively. 
  BP, bisphosphonate treatment (n=4 and 1 for CS and placebo, respectively); CS, chondroitin sulphate.     
  Table  1      Baseline  characteristics  
 Characteristic 
  CS (800 mg/day)   Placebo   
 (n=35)   (n=34)   p  Value 
Age (years) 59.7 ± 9.4 64.9 ± 9.5 0.025
BMI (kg/m  2  ) 30.4 ± 4.6 31.5 ± 5.2 0.381
Women (n (%)) 21 (60.0) 20 (58.8) >0.999
Cartilage volume (mm  3  ) 6347.1 ± 1815.5 6039.1 ± 1640.7 0.466
BML global score 1.8 ± 2.1 2.2 ± 2.2 0.372
Knee swelling and effusion 
(n (%))
19 (54.3) 22 (64.7) 0.465
Synovial membrane 
thickness (mm)
1.8 ± 0.55 1.8 ± 0.63 0.855
WOMAC total (0–2400) 1408.3 ± 357.3 1345.8 ± 430.5 0.513
VAS (0–100) 63.0 ± 15.9 62.3 ± 17.6 0.856
SF-36 general health (0–100) 70.3 ± 16.5 72.3 ± 16.7 0.617
      Baseline characteristics for the double-blind cohort (n=69). Data are expressed as 
mean ± SD or number of subjects (%) when appropriate. 
  BMI, body mass index; BML, bone marrow lesion; CS, chondroitin sulphate; SF-36, 
Short Form 36 General Health questionnaire; VAS, visual analogue scale; WOMAC, 
Western Ontario and McMaster Universities Osteoarthritis Index.     
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in the lateral compartment. Data from x-ray studies showed 
a protective effect of CS mainly in the medial compartment. 
These ﬁ  ndings are probably related to the design of these stud-
ies, as in those trials the JSW was measured only in the medial 
compartment.    5        6        8    A number of hypotheses could explain the 
predominant positive effect of CS treatment in the lateral com-
partment, including: (1) lesions are generally less severe in the 
lateral compartment than in the medial compartment and may 
be more responsive to treatment; (2) the effect of CS on the 
medial compartment could also take place at a later time during 
the treatment schedule (eg, 2 years).    7        8    The non-signiﬁ  cant effect 
of the drug seen on the trochlea could reﬂ  ect the distinct bio-
mechanical environment of the femoropatellar compartment. 
Our system did not allow for the detection of the cartilage in 
the patella, which could be considered a limitation of the ﬁ  nd-
ings. The signiﬁ  cant reduction in cartilage volume loss in the CS 
group was found to persist until the end of the open phase at the 
12-month follow-up. The reduction in the difference of the rate 
of cartilage loss between the two groups in the double-blind 
phase (  ﬁ  gure 2  ) could probably be explained by the fact that 
the placebo group started CS treatment at 6 months. Treatment 
with CS was effective at reducing both BML and cartilage vol-
ume loss in the same anatomical regions; however, a decrease 
in BML occurred only in the open phase (at 12 months). This 
glucosamine and CS,    53    as well as a structural analysis of the 
Glucosamine/chondroitin Arthritis Intervention Trial (GAIT)    54    
in which a non-ﬂ  uoroscopically guided x-ray technique was 
used and sample sizes were small, came to the conclusion that 
there is no treatment effect of CS. In general, the effect size was 
reported to be small to moderate, demonstrating the need for 
further trials that may conﬁ  rm the positive ﬁ  ndings of the pres-
ent trial and shed light on this controversial ﬁ  eld. 
  In the present study, the shorter time (6 months) needed 
to obtain signiﬁ  cant difference demonstrated the superiority 
of MRI in such studies. MRI has been shown to reliably and 
quantitatively assess cartilage volume and its changes over 
time in knee OA in longitudinal    15        23    and clinical    14    studies. With 
regard to this study, as age was signiﬁ  cantly different in the 
two groups the results were adjusted where appropriate and no 
relevant change overall was found. Of note, the observed rate 
of cartilage loss found in this study lies within the upper range 
of previous reports.    14        43        55        56    Here, CS treatment was found to 
signiﬁ  cantly reduce the cartilage volume loss at 6 months in 
the global knee, mainly in the lateral tibiofemoral compart-
ment and tibial plateaus. These ﬁ  ndings are in accordance with 
those of a previous MRI multicentre trial    14    in which a protec-
tive effect with the DMOAD licofelone was also detected as 
early as 6 months into the study, and was found predominantly 
  Figure  2         Cartilage volume loss in percentage and changes in bone marrow lesions (BML) score over time compared with baseline (0–6 months 
and 0–12 months). Solid line, chondroitin sulphate (CS) group; dotted line, placebo group. p Values of the corresponding subregions were assessed 
by analysis of covariance (ANCOVA) for the cartilage volume (where the dependent variable was the cartilage volume at 6 and 12 months and the 
independent variables were the cartilage volume at baseline and the treatment) and by the non-parametric Mann–Whitney U test for the BML scores. 
*p<0.05,**p<0.01. At 6 months n for cartilage: CS = 32, placebo = 28, for BML: CS = 32, placebo = 29. At 12 months n for cartilage: CS = 30, 
placebo = 22, for BML: CS = 30, placebo = 23. BL, baseline; m, months.       
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This ﬁ  nding contrasts with those from animal models    26        58     –      61    
and the GAIT,    62    in which CS treatment was associated with a 
signiﬁ  cant decrease in the incidence of joint swelling, effusion, 
or both upon clinical examination. The relatively small number 
of patients in the present pilot study could have been the limit-
ing factor explaining the data. 
  The effect of the combination of CS with NSAIDs on the 
synovial membrane thickness and the incidence of joint swell-
ing is interesting with practical clinical impact, and deﬁ  nitely 
needs future exploration. The absence of differences in dis-
ease symptoms between the placebo and CS groups could be 
explained by the use of rescue medication (paracetamol) as 
well as NSAIDs, which are strong confounding factors, and 
this may have masked an underlying symptom-relieving effect 
of CS. Moreover, as the severity of femoropatellar OA was 
not assessed, this might have been an additional confounding 
factor. The impact of the structure-modifying effect of CS on 
disease symptoms may also become clinically signiﬁ  cant only 
after an extended period of treatment. That question can only 
be answered by a long-term study. The study design included a 
double-blind phase (6 months) followed by an open-label phase 
(6 months) with CS treatment in both groups. This design does 
not allow for any conclusion regarding the symptom-relieving 
effects of CS, especially in the open-label phase, as the drop-
outs after unblinding occurred only in the placebo group result-
ing in a possible selection bias. The second phase was primarily 
chosen to gather additional information on the effects of CS on 
structural change. 
  The use of multiple analyses to compare the different struc-
tural changes has limitations, including the risks of ﬁ  nding signif-
icant results only by chance. Because of a relatively small study 
sample size, imbalances in baseline characteristics between the 
treatment groups may have had an impact on our results. For 
instance, even if there is a numerical difference (without statisti-
cal signiﬁ  cance) between treatment groups for variables such as 
BML scores and the presence of knee swelling and effusion, add-
ing these additional variables in the ANCOVA model would not 
yield any additional signiﬁ  cant information. Therefore, a conﬁ  r-
mation of these results in a larger trial is mandatory. 
  The safety proﬁ  le of CS was excellent and conﬁ  rms the ﬁ  nd-
ings of previous reports.    5     –      8        62        63    No SAE were found to be related 
to CS. 
  In summary, this pilot study demonstrates with the use of 
quantitative MRI a signiﬁ  cant reduction in cartilage volume loss 
as early as 6 months into treatment with CS and, for the ﬁ  rst 
time, a signiﬁ  cant reduction in BML size. These data underline 
not only the importance of the crosstalk between cartilage and 
subchondral bone in OA, but also their potential role in the 
disease process and response to DMOAD treatment. The anti-
inﬂ  ammatory effect of the combination of CS with NSAIDs is a 
new and interesting ﬁ  nding that deserves conﬁ  rmation in a deﬁ  n-
itive study. In conclusion, CS has been shown to be a safe drug 
with a positive global effect on OA joint structural changes.     
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ﬁ  nding could suggest that BML are consequential to cartilage 
degradation and thus reducing cartilage lesions could lead to 
fewer BML. Alternatively, BML were shown to be involved in 
an inﬂ  ammatory/catabolic  process    57    on which CS could act 
directly, leading to structural repair. The latter hypothesis is sup-
ported by in vitro data showing that CS increases the ratio of 
osteoprotegerin/receptor activator of nuclear factor-κB ligand, 
suggesting a positive effect on OA subchondral bone structural 
changes.    31    Data   also showed that CS treatment alone did not 
reduce the synovial membrane thickness (primary endpoint). 
  Table  3         Changes in bone marrow lesion scores (BML) versus baseline   
 Region   Month 
  CS (800 mg/day)   Placebo   
 Mean   SD   Mean   SD   p  Value 
Global 6 0.13 1.39 0.20 1.06 0.461
12 −0.57 1.83 0.43 1.70 0.062
Lateral compartment 6 0.03 0.40 0.13 0.43 0.153
12 −0.13 0.51 0.43 1.27 0.035
Medial compartment 6 0.09 1.28 0.07 1.01 1.000
12 −0.43 1.74 0.00 1.00 0.287
Condyles 6 0.09 0.78 0.07 0.78 0.879
12 −0.43 1.14 0.26 1.14 0.075
Lateral condyle 6 −0.03 0.18 0.07 0.25 0.085
12 −0.07 0.37 0.35 0.98 0.044
Medial condyle 6 0.13 0.75 0.00 0.74 0.432
12 −0.37 1.00 −0.09 0.73 0.450
Tibial plateaus 6 0.03 0.82 0.13 0.68 0.374
12 −0.13 0.94 0.17 0.98 0.347
Lateral tibial plateau 6 0.06 0.35 0.07 0.37 0.644
12 −0.07 0.25 0.09 0.67 0.358
Medial tibial plateau 6 −0.03 0.74 0.07 0.52 0.303
12 −0.07 0.91 0.09 0.73 0.732
Trochlea 6 0.16 0.63 0.00 0.45 0.379
12 −0.07 0.94 0.13 0.63 0.222
      p Values were assessed by two-sided Mann–Whitney U test. 
  n=32/30 for CS, n=29/23 for placebo at 6 and 12 months, respectively. 
 CS,  chondroitin  sulphate.   
  Table  4      Adverse  events  
 Adverse  event 
 Double-blind
  0–6  months 
 Double-blind/open-label  
0–12 months 
 CS   Placebo   CS/CS   Placebo/CS 
 n=35   n=35   n=32   n=30 
Total non-serious adverse 
events
55 38 47 32
 Eye  disorders 1 0 1 0
 Gastrointestinal  disorders 7 7 7 5
  General (peripheral oedema) 1 2 1 1
 Infections 12 6 4 3
 Injury/poisoning 6 4 3 5
 Investigations  (creatinine 
increased)
10 1 0
  Metabolism and nutrition 0 2 0 0
 Musculoskeletal 13 12 13 13
 Nervous  system 4 2 5 2
 Psychiatric  disorders 1 2 1 3
  Renal and urinary disorders 0 1 0 0
 Skin  disorders 8 0 7 0
 Surgical  procedures 1 2 0 0
 Vascular  disorders 0 0 2 0
Total serious adverse events 1 1 1 2
 Atrial  ﬁ   brillation 1 0 0 0
 Cholecystitis 0 1 0 0
 Knee  arthroplasty 0 0 1 1
 Syncope 0 0 0 1
   CS,  chondroitin  sulphate  (800  mg/day).   
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